ISIN | LU0090689299 |
---|---|
Valor Number | 891431 |
Bloomberg Global ID | BBG000LMWC41 |
Fund Name | Pictet-Biotech -P USD |
Fund Provider |
Pictet Asset Management S.A.
Genève, Switzerland Phone: +41 58 323 10 24 www.assetmanagement.pictet |
Fund Provider | Pictet Asset Management S.A. |
Representative in Switzerland |
Pictet Asset Management S.A. Genève 73 Phone: +41 58 323 30 00 |
Distributor(s) |
Credit Suisse AG Zürich Phone: +41 44 333 11 11 UBS AG Zürich Phone: +41 44 234 11 11 Vontobel Fonds Services AG Zürich Phone: +41 58 283 74 77 |
Asset Class | Equities |
EFC Category | Equity Health Care |
Distribution Policy | Accumulation |
Home Country | Luxembourg |
Issuing Condition | The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel) |
Redemption Condition | The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel) |
Investment Strategy *** | To increase the value of your investment while seeking to achieve a positive social impact. The Fund applies a sustainable strategy and invests at least two-thirds of its net assets in equities or similar securities issued by biopharmaceutical companies throughout the world. Companies supporting the health of people with high innovation capacity. Better therapies can deliver true value to patients and healthcare systems alike. These companies are tackling high unmet medical needs and reduce the pressures on healthcare budgets through the reduction of hospital admissions or symptom management. The Fund invests mainly in companies whose significant proportion of their activities are related to, but not limited to, new mechanisms of actions offering potential cures or management of diseases that were hard to treat before, technology platforms, research tools and services in the biotechnology value chain as well as the improvement of therapies or drugs. |
Peculiarities |
Current Price * | 888.66 USD | 23.12.2024 |
---|---|---|
Previous Price * | 887.49 USD | 20.12.2024 |
52 Week High * | 1,034.07 USD | 11.11.2024 |
52 Week Low * | 830.04 USD | 25.04.2024 |
NAV * | 888.66 USD | 23.12.2024 |
Issue Price * | ||
Redemption Price * | ||
Closing Price * | ||
Indicative Minimum Price | ||
Fund Assets *** | 1,502,865,126 | |
Unit/Share Assets *** | 422,358,534 | |
Trading Information SIX |
YTD Performance | -0.71% |
29.12.2023 - 23.12.2024
29.12.2023 23.12.2024 |
---|---|---|
YTD Performance (in CHF) | +5.44% |
29.12.2023 - 23.12.2024
29.12.2023 23.12.2024 |
1 month | -7.79% |
25.11.2024 - 23.12.2024
25.11.2024 23.12.2024 |
3 months | -9.82% |
23.09.2024 - 23.12.2024
23.09.2024 23.12.2024 |
6 months | -4.24% |
24.06.2024 - 23.12.2024
24.06.2024 23.12.2024 |
1 year | -0.28% |
27.12.2023 - 23.12.2024
27.12.2023 23.12.2024 |
2 years | +11.34% |
23.12.2022 - 23.12.2024
23.12.2022 23.12.2024 |
3 years | -3.76% |
23.12.2021 - 23.12.2024
23.12.2021 23.12.2024 |
5 years | +9.85% |
23.12.2019 - 23.12.2024
23.12.2019 23.12.2024 |
Equity Participation Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Real Estate Rate in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI | 0.5573 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ADDI Date | 23.12.2024 |
argenx SE ADR | 5.67% | |
---|---|---|
Insmed Inc | 4.52% | |
Sarepta Therapeutics Inc | 4.05% | |
Intra-Cellular Therapies Inc | 4.01% | |
TG Therapeutics Inc | 3.30% | |
Vaxcyte Inc Ordinary Shares | 3.24% | |
Blueprint Medicines Corp | 3.10% | |
Gilead Sciences Inc | 3.01% | |
SpringWorks Therapeutics Inc Ordinary Shares | 2.81% | |
Cytokinetics Inc | 2.80% | |
Last data update | 30.11.2024 |
TER *** | 1.992% |
---|---|
TER date *** | 31.05.2024 |
Performance Fee *** | |
PTR | |
Max. Management Fee *** | 2.40% |
Ongoing Charges *** | 1.99% |
SRRI ***
|
|
SRRI date *** | 30.11.2024 |
Low Carbon Designation *** | |
---|---|
ESG Rating Overall *** | |
ESG Rating Corporate *** | |
ESG Rating Sovereign *** | |
% AuM H&S Controversies *** |
Avg Carbon Risk Score *** | |
---|---|
Avg Carbon Risk Cat Avg *** | |
% AuM Covered Carbon *** | |
Avg Fossil Fuel Exposure *** | |
Fossil Fuel Cat Avg *** |
Strategy Level 1 *** | |
---|---|
Strategy Level 2 *** | |
Strategy Level 3 *** | |
Exclusions Level 1 *** | |
Exclusions Level 2 *** |
GMOs |